Related Experiment Video

Updated: Sep 23, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth

Yuebo Zhang1, Yong Ma2, Ying Wang3

  • 1Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.

Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|May 13, 2022
PubMed

Insights

Aurora kinase-A is elevated in pancreatic cancer. Its inhibitor, MLN8237, reduced tumor growth and cell proliferation, offering a potential new chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC) patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate.
  • Limited effective chemotherapy options exist for PDAC.
  • Aurora kinase-A expression is elevated in PDAC.

Purpose of the Study:

  • To investigate the role of Aurora kinase-A in PDAC.
  • To evaluate the efficacy of MLN8237, an Aurora kinase-A inhibitor, as a potential PDAC therapy.

Main Methods:

  • Assessed Aurora kinase-A expression in human and mouse PDAC samples.
  • Tested MLN8237's effect on PDAC cell proliferation and motility in vitro.
  • Evaluated MLN8237's anti-tumor efficacy in vivo using xenograft and genetic mouse models.

Main Results:

  • MLN8237 significantly reduced PDAC cell proliferation and motility in vitro.
  • MLN8237 inhibited tumor growth in vivo.
  • MLN8237 demonstrated anti-tumor effects by inhibiting proliferation, migration, and inducing apoptosis and senescence.

Conclusions:

  • Aurora kinase-A is a potential therapeutic target in PDAC.
  • MLN8237 shows promise as a novel chemotherapy agent for PDAC.
  • This study provides a molecular basis for developing new PDAC treatments.
Keywords:
ApoptosisAurora kinasePancreatic cancerSenescenceXenograft

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.5K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K